Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1067/mai.2002.126817 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Disposition of emergency department patients presenting with angiotensin-converting enzyme inhibitor-induced angioedema.
Int J Emerg Med
January 2025
Department of Emergency Medicine, Wake Forest Baptist Medical Center, 475 Vine Street, Winston-Salem, NC, 27101, USA.
Background: Angiotensin-converting enzyme inhibitors (ACEI) are the most common cause of drug-induced angioedema in the United States. Our primary objective was to provide descriptive evidence regarding emergency department (ED) disposition of ACEI-induced angioedema patients. Our secondary objective was to evaluate unique patterns in those with ACEI-induced angioedema at a tertiary referral center, including demographics, details of those requiring intubation, length of inpatient stay, and allergy documentation.
View Article and Find Full Text PDFA Case of Ramipril-Induced Angioedema and Solar Purpura.
Adv Skin Wound Care
January 2025
In the Department of Dermatology, Faculty of Medicine, Sakarya University, Turkey, Rabia Oztas Kara, MD, is Assistant Professor and Bahar Sevimli Dikicier, MD, is Associate Professor. In the Department of Pathology, Bilge Elcin, MD, is Specialist.
This case report describes a patient who developed solar purpura after treatment for angioedema associated with ramipril, an angiotensin-converting enzyme inhibitor. The patient presented to the ED with angioedema. She had been using ramipril for 2 years.
View Article and Find Full Text PDFAngioedema.
Allergy Asthma Clin Immunol
December 2024
Division of Allergy and Immunology, Department of Medicine, Western University, London, ON, Canada.
Angioedema can occur in the absence of urticaria and can be broadly divided into three main categories: mast cell-mediated (e.g., histamine), non-mast-cell-mediated (bradykinin-induced) and idiopathic angioedema.
View Article and Find Full Text PDFValsartan/Sacubitril induced isolated angioedema of uvula: A case report.
Heliyon
November 2024
Department of Radiology, Ibn Sina Specialized Hospital, Jenin, P200, Palestine.
Objective: To report a case of drug-induced isolated angioedema secondary to the use of Entresto (Valsartan/Sacubitril).
Case Summary: A 75-year-old White man presented with swelling of the uvula with a normal tongue shape and gradual onset of speech difficulty, shortness of breath, and difficulty swallowing after taking his chronic medication Entresto (sacubitril/valsartan). The main possibility considered was uvular angioedema, other potential causes were not identified.
Angiotensin-Converting Enzyme Inhibitor Washout Period Prior to Angiotensin Receptor/Neprilysin Inhibitor Initiation in the Inpatient Setting.
Ann Pharmacother
November 2024
Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Aurora, CO, USA.
Background: The 2022 AHA-ACC HFSA Guideline for Management of Heart Failure recommend initiating an angiotensin receptor/neprilysin inhibitor (ARNI) in patients with heart failure with reduced ejection fraction (HFrEF) who can tolerate an angiotensin-converting enzyme inhibitor (ACEi). The manufacturer recommends initiating a 36-hour washout period when switching from ACEi to ARNI due to an increased risk of adverse effects, including angioedema. This study investigated the adherence to the washout period when transitioning from ACEi to ARNI at a community hospital.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!